title: Effects of a beta-adrenergic agonist (L-644,969) and male sex condition on muscle growth and meat quality of callipyge lambs.
abstract: The objective of this study was to determine the effects of dietary administration of a beta-adrenergic agonist (BAA; L-644,969) and male sex condition (ram vs wether) on muscle growth and meat quality of Dorset x Romonov lambs believed to be heterozygous for the callipyge gene. At approximately 17 wk of age, lambs were blocked by weight within each sex condition and randomly assigned to BAA treatment group. The interaction of BAA and male sex condition was not significant for any of the traits measured. Rams had greater initial and final live weights, average daily gain, and hot carcass weight (P < .01). Rams did not differ (P > .05) from wethers with respect to any of the carcass traits, possibly because the wethers were so lean and heavily-muscled that there was little room for improvement. Kidney-pelvic fat weight was reduced 26% by BAA (P < .05). Knife separable lean weight and whole carcass proximate composition were not affected (P > .05) by BAA or male sex condition. Administration of BAA increased calpastatin activity at 20 d (1.1 vs 1.5 units/g), but not at 0 h (3.9 vs 4.8 units/g) postmortem, decreased myofibril fragmentation index (60.7 vs 44.9), and increased shear force (8.2 vs 10.9 kg) at 20 d postmortem (P < .05). These data suggest that muscle growth rates are near maximum in lambs expressing the callipyge gene, regardless of male sex condition or BAA treatment. Therefore, it seems that the callipyge gene exerts most, but not all, of its effect through intracellular events similar to those initiated by administering BAA.
authors.affiliation: Roman L. Hruska U.S. Meat Animal Research Center, ARS, USDA, Clay Center, NE 68933-0166, USA.
authors.forename: M
authors.initials: M
authors.lastname: Koohmaraie
authors.forename: S D
authors.initials: SD
authors.lastname: Shackelford
authors.forename: T L
authors.initials: TL
authors.lastname: Wheeler
mesh_terms: D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001823:Body Composition / Q000502:physiology; D001835:Body Weight / Q000502:physiology; D002135:Calcium-Binding Proteins / Q000032:analysis; D004032:Diet; D006579:Heterozygote; D006863:Hydrogen-Ion Concentration; D008297:Male; D008460:Meat / Q000592:standards*; D024510:Muscle Development; D018482:Muscle, Skeletal / Q000737:chemistry / Q000187:drug effects / Q000254:growth & development*; D009919:Orchiectomy / Q000662:veterinary*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D012756:Sheep / Q000235:genetics* / Q000502:physiology*; D013696:Temperature; D015430:Weight Gain / Q000502:physiology
chemical_list: D000318:Adrenergic beta-Agonists; D002135:Calcium-Binding Proteins; D011725:Pyridines; C061557:6-amino-alpha-(((1-methyl-3-phenylpropyl)amino)methyl)-3-pyridine methanol; C033668:calpastatin